Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Plasmacytoma 1Multiple Myeloma 1Carcinoma, Basal Cell 1

Interventions

Dexamethasone 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1filanesib 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Steroids 1Specimen Handling 1Sodium Selenite 1Radiotherapy 1Radiation 1Proteasome Inhibitors 1Lenalidomide 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Calcium Dobesilate 1Bortezomib 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Plasmacytoma × silmitasertib × Clear all
NCT01199718 2011-06-15

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Cylene Pharmaceuticals

Phase 1 Unknown
22 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡